

7 January 2026

ASX Announcement

Additional US Patent Granted for Galidesivir in Marburg and other filoviridae viruses

- **US Patent Number 12,508,266 granted by the US Patent and Trademark Office for the use of Galidesivir in the treatment of filoviridae viruses**
- **Provides IP protection through October 2031 for the use of Galidesivir to treat a broad range of viruses in the filoviridae virus family**
- **Filoviridae viruses includes Marburg and Ebola – both areas of focus for Island, based on clinically significant historical data associated with Galidesivir**
- **Marks ongoing execution of Island's stated strategy to expand patent protections for the Galidesivir program alongside clinical development**

MELBOURNE Australia, 7 January 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise it has been granted US Patent Number 12,508,266 by the US Patent and Trademark Office ('USPTO') for the use of Galidesivir in the treatment of filoviridae viruses.

The patent comprises a broad range of claims in connection with the treatment of a viral infections from the filoviridae family, via the administering of a therapeutically effective amount of Galidesivir.

Patent protection for the use of Galidesivir to treat filoviridae viruses marks the latest successful conversion from application to approval for the diversified patent portfolio that Island gained full rights to as part of its acquisition of the Galidesivir program.

The patent portfolio comprised both issued patents and pending patent applications, with each new approval strengthening the framework for Island to continue broadening its IP footprint alongside the clinical development pathway for Galidesivir.

The latest approval provides Island with patent protection for a broad range of claims through to 14 October 2031 covering the application of Galidesivir to filoviridae - a family of single-stranded negative-sense RNA viruses, of which the most commonly known are the Ebola virus and the Marburg virus.

The patent is well aligned with Island's stated clinical development strategy for Galidesivir, following confirmation in November 2025 regarding Galidesivir's approval pathway for use in Marburg under the FDA's Animal Rule (*refer ASX Announcement 17 November 2025*).

Filoviridae viruses are generally recognised by the US government as biological select agents or toxins (BSAT), which have been classified by the US Department of Health and Human Services as having the potential to pose a severe threat to public health and safety.



It follows the receipt last month of USPTO patent number 12,472,197 which provided Island with US patent protection to pursue treatment options for Covid-19 infections using Galidesivir (refer ASX Announcement 5 December 2025).

Management commentary:

CEO and Managing Director, Dr David Foster said: *"This latest patent grant highlights that our IP footprint continues to go from strength to strength, and further validates the vigour of the patent portfolio that we gained full ownership rights of as part of the Galidesivir acquisition."*

"What is particularly pleasing about this patent is that it provides IP protection over a broad range of claims in the application of Galidesivir to treat filoviruses, in direct alignment with detailed clinical development pathway for the treatment of Marburg – a member of the filoviridae virus family."

"As we continue to advance the study design in close consultation with the FDA, this patent approval provides a strong framework to further expand our IP footprint alongside our clinical progress."

- Ends -

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.